Analysts' Top Healthcare Picks: Humacyte (HUMA), Janux Therapeutics Inc (JANX)
TipRanksApr 11 09:10
Oppenheimer Keeps Their Buy Rating on Humacyte (HUMA)
TipRanksApr 8 20:25
Humacyte Analyst Ratings
BenzingaApr 1 20:27
Cantor Fitzgerald Reiterates Overweight on Humacyte, Maintains $7 Price Target
BenzingaApr 1 20:28
Piper Sandler Maintains Neutral on Humacyte, Maintains $4 Price Target
BenzingaMar 26 20:26
Piper Sandler Sticks to Its Hold Rating for Humacyte (HUMA)
TipRanksMar 26 19:06
Humacyte Analyst Ratings
BenzingaMar 25 22:45
Humacyte's Strong Outlook: Buy Rating Affirmed Amid Advancements and Market Opportunity
TipRanksMar 23 22:35
Buy Rating for Humacyte: Anticipated FDA Approval and Strong Financials Signal Growth Potential
TipRanksMar 23 01:35
Humacyte Analyst Ratings
BenzingaMar 8 21:31
Piper Sandler Reaffirms Their Hold Rating on Humacyte (HUMA)
TipRanksMar 8 20:48
Analysts Offer Insights on Healthcare Companies: Embecta Corporation (EMBC), Mettler-Toledo (MTD) and Humacyte (HUMA)
TipRanksFeb 12 01:01
Buy Rating Justified by FDA Review and Commercial Prospects for Humacyte's HAV Device
TipRanksFeb 10 02:25
Humacyte (HUMA) Gets a Buy From BTIG
TipRanksJan 2 22:22
Benchmark Maintains Buy on Humacyte, Lowers Price Target to $15
BenzingaDec 28, 2023 03:23
Humacyte Analyst Ratings
BenzingaDec 28, 2023 03:22
Benchmark Co. Sticks to Their Buy Rating for Humacyte (HUMA)
TipRanksDec 27, 2023 20:35
Humacyte Analyst Ratings
BenzingaDec 11, 2023 19:20
Promising Clinical Trials and Innovative Technology Bolster Buy Rating for Humacyte Stock
TipRanksNov 18, 2023 01:25
Piper Sandler Maintains Neutral on Humacyte, Lowers Price Target to $3-Report Released on 9th Nov 2023
BenzingaNov 11, 2023 06:16
No Data
No Data